RELATED REPORTS
Tags: blood cancerbortezomibcancerchemotherapydexamethasoneelotuzumabhematologyhigh-risk multiple myelomaimmunomodulator therapyimmunomodulatorsinductionlenalidomidemaintenanceMMmotor neuropathymultiple myelomamyelomaneuropathyoncologypfsphase 2 trialprogression-free survivalproteasome inhibitorrandomisedrandomised trialRVdsensory neuropathy
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)






